|Basic InformationMore InformationLatest News|Study Supports Using Low-Dose CT Scans to Spot Early Lung CancerComorbidities Up Other-Cause Death for Men With Prostate CARacial Disparities Seen in U.S. Lung Cancer TreatmentNewer, Pricier Prostate Cancer Radiation No Better Than Old: StudyHIV No Barrier to Getting Liver Transplant, Study FindsXofigo Approved for Prostate CancerTest Approved to Detect Faulty Lung Cancer GeneNew Drug May Help Immune System Fight CancerCancer Patients May Face Higher Bankruptcy OddsFDA Approves New Drug to Fight Advanced Prostate CancerMetformin Won't Aid Breast Cancer Survival in DiabeticsCreative Arts Therapies Up Mental Health for Cancer PatientsExperts Aim to Draw Attention to High Cancer Drug CostsCreative Arts May Help Cancer Patients CopeAgent Orange Tied to Lethal Prostate CancerScientists Discover More Genetic Clues to Testicular CancerSocializing May Ease Pain of Breast CancerGene Discovery May Offer Breakthrough for Rare LeukemiaRed Hair Pigment Might Raise Melanoma Risk: StudySkin Cancer Tx Mostly Surgical, Regardless of Life ExpectancyAATS: MnDCT Beats Chest X-Ray for Detecting Lung CancerProstate Cancer May Be Deadlier for the UninsuredSleep Woes Tied to Prostate Cancer Risk in StudyAUA: Incidence of Testicular Cancer Up Through 2009Study Links Timing of ER Visit to Prostate Cancer Survival OddsTesticular Cancer on Rise in U.S., Especially Among Hispanic MenUrologists' Group Issues Updated Guidelines on PSA TestAt-Home Drug Errors Common for Kids With Cancer, Research ShowsScientists Pinpoint Most Major Genes Behind Deadly Blood CancerImplants May Delay Breast Cancer Detection, Raise Death RiskComprehensive Analysis Supports SERMs for Cutting Breast CancerNovel System Proposed for Accountable Cancer CareWomen Smokers More Likely to Get Colon Cancer Than Men: StudyFor Some Seniors With Skin Cancer, Surgery Not Always Best ChoiceComprehensive Discussion With Docs Ups Cancer ScreeningHistory of Skin Cancer Linked to Secondary CancersIntegrated 2D, 3D Mammogram Improves Cancer DetectionSoaring Prices Keep Leukemia Drugs From Patients, Experts SayRace, Income Tied to Breast Cancer Treatment Delays, Reduced SurvivalObesity Tied to Risk of Prostate Cancer After Negative BiopsyNon-Melanoma Skin Cancers Tied to Risk for Other CancersObesity Linked to Prostate Cancer, Study FindsMammograms Can Measure How Breast Cancer Drug Is Working: StudyScientists Spot Cancer Metabolism ChangesMinorities Less Prone to Think They'll Get Cancer: StudyClinical Trials Helped One Woman's Fight Against CancerARRS: MASS Criteria, LDH Predict Survival in MelanomaScientists Create Breast Cancer Survival PredictorEndocrine Therapy Often Incomplete after Breast CancerEndometriosis Surgery Linked to Lower Ovarian Cancer RiskLinksBook Reviews
Novel Agent Tolerable, Active for Advanced Colorectal Cancer
Updated: Aug 28th 2012
TUESDAY, Aug. 28 (HealthDay News) -- For patients with previously treated metastatic colorectal cancer who are refractory or intolerant to standard therapies, treatment with a novel oral nucleoside antitumor agent, TAS-102, is tolerable and shows promising efficacy, according to a phase 2 study published online Aug. 28 in The Lancet Oncology.
Takayuki Yoshino, M.D., from the National Cancer Center Hospital East in Chiba, Japan, and colleagues assessed the efficacy and safety of TAS-102 for patients with confirmed colorectal adenocarcinoma who had a treatment history of two or more regimens of standard chemotherapy and were refractory or intolerant to fluoropyrimidine, irinotecan, and oxaliplatin. A total of 112 patients (aged 20 or older) were randomly assigned to receive TAS-102, and 57 patients were assigned to placebo. Patients were followed for a median of 11.3 months.
The researchers found that the median overall survival was significantly longer in the TAS-102 group compared with the placebo group (9.0 versus 6.6 months; hazard ratio, 0.56). In the safety population, 50 percent of TAS-102-treated patients had neutropenia of grade 3 or 4, 28 percent had leukopenia, and 17 percent had anemia. None of the placebo-treated patients had grade 3 or worse neutropenia or leukopenia; 5 percent had grade 3 or worse anemia. Serious adverse events occurred in 19 percent of the TAS-102-treated and 9 percent of placebo-treated patients. There were no treatment-related deaths.
"In conclusion, TAS-102 has promising efficacy with a manageable safety profile in patients with metastatic colorectal cancer who are refractory or intolerant to standard chemotherapy," the authors write.
Several authors disclosed financial ties to pharmaceutical companies, including Taiho Pharmaceuticals, which funded the study and manufactures TAS-102.
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
This article: Copyright © 2012 HealthDay. All rights reserved.